These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Langton Hewer SC; Smyth AR Cochrane Database Syst Rev; 2014 Nov; (11):CD004197. PubMed ID: 25383937 [TBL] [Abstract][Full Text] [Related]
3. Unveiling the early events of Pseudomonas aeruginosa adaptation in cystic fibrosis airway environment using a long-term in vitro maintenance. Sousa AM; Monteiro R; Pereira MO Int J Med Microbiol; 2018 Dec; 308(8):1053-1064. PubMed ID: 30377031 [TBL] [Abstract][Full Text] [Related]
4. Intravenous or oral antibiotic treatment in adults and children with cystic fibrosis and Pseudomonas aeruginosa infection: the TORPEDO-CF RCT. Langton Hewer SC; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Sutton L; Clayton D; Arch B; Tanajewski Ł; Berdunov V; Williamson PR Health Technol Assess; 2021 Nov; 25(65):1-128. PubMed ID: 34806975 [TBL] [Abstract][Full Text] [Related]
5. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Langton Hewer SC; Smyth AR Cochrane Database Syst Rev; 2009 Oct; (4):CD004197. PubMed ID: 19821321 [TBL] [Abstract][Full Text] [Related]
6. Eradication of early Pseudomonas infection in cystic fibrosis. Lee TW Chron Respir Dis; 2009; 6(2):99-107. PubMed ID: 19411571 [TBL] [Abstract][Full Text] [Related]
7. Pseudomonas aeruginosa and the airways disease of cystic fibrosis. Hata JS; Fick RB Clin Chest Med; 1988 Dec; 9(4):679-89. PubMed ID: 3148384 [TBL] [Abstract][Full Text] [Related]
8. Clearance of initial mucoid Pseudomonas aeruginosa in patients with cystic fibrosis. Troxler RB; Hoover WC; Britton LJ; Gerwin AM; Rowe SM Pediatr Pulmonol; 2012 Nov; 47(11):1113-22. PubMed ID: 22496040 [TBL] [Abstract][Full Text] [Related]
9. Transcriptome Analysis of Pseudomonas aeruginosa Biofilm Infection in an Harrington NE; Littler JL; Harrison F Appl Environ Microbiol; 2022 Feb; 88(3):e0178921. PubMed ID: 34878811 [TBL] [Abstract][Full Text] [Related]
10. The treatment of respiratory pseudomonas infection in cystic fibrosis: what drug and which way? Banerjee D; Stableforth D Drugs; 2000 Nov; 60(5):1053-64. PubMed ID: 11129122 [TBL] [Abstract][Full Text] [Related]
11. Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis. Smith S; Waters V; Jahnke N; Ratjen F Cochrane Database Syst Rev; 2020 Jun; 6(6):CD009528. PubMed ID: 32520436 [TBL] [Abstract][Full Text] [Related]
12. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2015 Nov; (11):CD006961. PubMed ID: 26522473 [TBL] [Abstract][Full Text] [Related]
13. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Wood DM; Smyth AR Cochrane Database Syst Rev; 2006 Jan; (1):CD004197. PubMed ID: 16437476 [TBL] [Abstract][Full Text] [Related]
14. Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial. Hewer SCL; Smyth AR; Brown M; Jones AP; Hickey H; Kenna D; Ashby D; Thompson A; Williamson PR; Lancet Respir Med; 2020 Oct; 8(10):975-986. PubMed ID: 33007285 [TBL] [Abstract][Full Text] [Related]